Brief: Acceptable Safety At Highest Dose Tested In Bergenbio's Phase 1B Study Confirmed
29/07/2024 06:15
July 29 (Reuters) - Bergenbio ASA BGBIO.OL :
* DATA AND SAFETY MONITORING BOARD (DSMB) FOR BERGENBIO'S PHASE 1B/2A BGBC016 STUDY
CONFIRMED
ACCEPTABLE SAFETY AT HIGHEST DOSE TESTED IN PHASE 1B
Source text for Eikon: ID:nObikmTvba
Further company coverage: BGBIO.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee